Sundyota Numandis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.30 Cr
as on 24-10-2024
- Paid Up Capital ₹ 3.30 Cr
as on 24-10-2024
- Company Age 21 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 65.43 Cr
as on 24-10-2024
- Satisfied Charges ₹ 5.39 Cr
as on 24-10-2024
- Revenue 10.98%
(FY 2023)
- Profit 59.17%
(FY 2023)
- Ebitda 48.69%
(FY 2023)
- Net Worth 20.14%
(FY 2023)
- Total Assets 8.76%
(FY 2023)
About Sundyota Numandis Pharmaceuticals
The Corporate was formerly known as Dyota Numandis Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.30 Cr and a paid-up capital of Rs 3.30 Cr.
The company currently has active open charges totaling ₹65.43 Cr. The company has closed loans amounting to ₹5.39 Cr, as per Ministry of Corporate Affairs (MCA) records.
Dinesh Arora and Poonam Arora serve as directors at the Company.
- CIN/LLPIN
U24239GJ2003PTC042438
- Company No.
042438
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 May 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sundyota Numandis Pharmaceuticals Private Limited offer?
Sundyota Numandis Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Pre & Probiotic Capsule.
Who are the key members and board of directors at Sundyota Numandis Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Arora  | Managing Director | 29-May-2003 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Poonam Arora | Director | 29-May-2003 | Current |
Financial Performance of Sundyota Numandis Pharmaceuticals.
Sundyota Numandis Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.98% increase. The company also saw a substantial improvement in profitability, with a 59.17% increase in profit. The company's net worth Soared by an impressive increase of 20.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sundyota Numandis Pharmaceuticals?
In 2023, Sundyota Numandis Pharmaceuticals had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sundyota Numandis Probioceuticals Private LimitedActive 13 years 2 monthsDinesh Arora is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 25 Jan 2019 | ₹17.28 Cr | Open |
State Bank Of India Creation Date: 25 Jan 2019 | ₹41.50 Cr | Open |
Others Creation Date: 22 Sep 2009 | ₹6.65 Cr | Open |
How Many Employees Work at Sundyota Numandis Pharmaceuticals?
Sundyota Numandis Pharmaceuticals has a workforce of 333 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sundyota Numandis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sundyota Numandis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
